Press |

Kosteneffectiviteit pembrolizumab bij blaaskanker

In European Urology Oncology de abstract van de studie Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.

De conclusie luidt:

‘The results show that pembrolizumab is a cost-effective option for first-line treatment of locally advanced or metastatic urothelial carcinoma in cisplatin-ineligible patients with strongly PD-L1–positive tumours in Sweden at a willingness-to-pay threshold of s100 000, with potential survival and QALY benefit compared to che-motherapies.’


© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in